SEC EDGAR · Financial report
ABT: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
Follow ABT- Became public
- Jul 28, 2026, 4:02 PM EDT
- Event / period date
- Jun 30, 2026
- Collected
- Nov 9, 2026, 3:27 PM EST
Why this is connected
This filing identifies ABBOTT LABORATORIES as the issuer of the security. The company's SEC identifier connects it to ABT.
Source evidence
Read the source excerpt or record
abt-20260630 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 ABBOTT LABORATORIES An Illinois Corporation I.R.S. Employer Identification No. 36-0698440 100 Abbott Park Road Abbott Park , Illinois 60064-6400 Telephone: ( 224 ) 667-6100 Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange NYSE Texas Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12
Price change after we could observe it
-1.06% ABT
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in ABT
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
Bought Abbott Laboratories ABT
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
Traded 14 days before earnings - Oct 30, 2026$1K–$15K
Rep. Thomas H. Kean, Jr. (R-NJ-7)
Sold (partial) Abbott Laboratories ABT
$1K–$15K · Traded Sep 17, 2026 · disclosed Oct 30, 2026
Committee overlap: Energy and Commerce - Oct 27, 2026$50K–$100K
Rep. Pete Sessions (R-TX-17)
$50K–$100K · Traded Oct 2, 2026 · disclosed Oct 27, 2026 · Spouse
- Oct 12, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Abbott Laboratories ABT
$1K–$15K · Traded Sep 18, 2026 · disclosed Oct 12, 2026
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Abbott Laboratories ABT
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 18, 2026$15K–$50K
Rep. Rick W. Allen (R-GA-12)
$15K–$50K · Traded Jul 14, 2026 · disclosed Aug 18, 2026 · Spouse
Committee overlap: Energy and CommerceTraded 2 days before earnings - Aug 14, 2026$1K–$15K
Rep. Richard McCormick (R-GA-7)
$1K–$15K · Traded Jul 30, 2026 · disclosed Aug 14, 2026
Got $2K from the company’s PAC - Aug 12, 2026$1K–$15K
Rep. Mike Kelly (R-PA-16)
$1K–$15K · Traded Jul 17, 2026 · disclosed Aug 12, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.